FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marc Ychou

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Thierry Conroy; Céline Gavoille; Emmanuelle Samalin; Marc Ychou; Michel Ducreux
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Axel Grothey; Yves Humblet; Dirk Laurent; Heinz-Josef Lenz; Laurent Mineur; Daniel J Sargent; Salvatore Siena; Alberto Sobrero; Josep Tabernero; Eric Van Cutsem; Andrea Wagner; Marc Ychou; Takayuki Yoshino; Antoine Adenis; Carlo Barone; Olivier Bouché; Frank Cihon; Lisa Cupit; Alfredo Falcone; Richard M Goldberg
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Sophie Gourgou-Bourgade; Rosine Guimbaud; Jean-Luc Raoul; Marc Ychou; Antoine Adenis; Caroline Bascoul-Mollevi; Yves Bécouarn; Jocelyne Bérille; Valérie Boige; Olivier Bouché; Françoise Desseigne; Thierry Conroy
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marc Ychou (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thierry Conroy; Céline Gavoille; Emmanuelle Samalin; Marc Ychou; Michel Ducreux
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Current oncology reports 2013;15(2):182-9.
2013: Axel Grothey; Yves Humblet; Dirk Laurent; Heinz-Josef Lenz; Laurent Mineur; Daniel J Sargent; Salvatore Siena; Alberto Sobrero; Josep Tabernero; Eric Van Cutsem; Andrea Wagner; Marc Ychou; Takayuki Yoshino; Antoine Adenis; Carlo Barone; Olivier Bouché; Frank Cihon; Lisa Cupit; Alfredo Falcone; Richard M Goldberg
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet 2013;381(9863):303-12.
2013: Sophie Gourgou-Bourgade; Rosine Guimbaud; Jean-Luc Raoul; Marc Ychou; Antoine Adenis; Caroline Bascoul-Mollevi; Yves Bécouarn; Jocelyne Bérille; Valérie Boige; Olivier Bouché; Françoise Desseigne; Thierry Conroy
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(1):23-9.
2012: Manfred P Lutz; Christophe Mariette; Markus Moehler; Florian Otto; Tsuneo Oyama; Arnaud Roth; Josef Rueschoff; Thomas Ruhstaller; Raquel Seruca; Michael Stahl; Florian Sterzing; Eric van Cutsem; Ate van der Gaast; Jan van Lanschot; Marc Ychou; John R Zalcberg; Jaffer A Ajani; William Allum; Daniela Aust; Yung-Jue Bang; Stefano Cascinu; Michel Ducreux; Arnulf Hölscher; Janusz Jankowski; Edwin P M Jansen; Ralf Kisslich; Florian Lordick
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
European journal of cancer (Oxford, England : 1990) 2012;48(16):2941-53.
2012: Z Reguiai; M A Richard; Emmanuelle Samalin; Marc Ychou; T André; Pascal Artru; J B Bachet; C Bachmeyer; R J Bensadoun; Marie Beylot-Barry; M Bezier; E Boucher; C Chevelle; P Colin; B Dreno; P Dufour; J M Gornet; R Guimbaud; Laurent Mineur; L Peuvrel; Olivier Bouché
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2012;20(7):1395-404.
2012: Stephanie Nougaret; MA Pierredon; Caroline Reinhold; Philippe Rouanet; Marc Ychou; eric assenat; David Azria; Frederic Bibeau; Jacqueline Duffour; Claire Lemanski; Nicolas Molinari; Benoît P Gallix
MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.
Radiology 2012;263(2):409-18.
2012: Romain Altwegg; Ludovic Caillo; Stéphanie Faure; Nicolas Flori; Vanessa Guillaumon; Thibault Mazard; Emmanuelle Samalin; Pierre Senesse; Simon Thezenas; Marc Ychou; eric assenat
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
World journal of gastroenterology : WJG 2012;18(12):1357-64.
2012: T Mazard; Frédéric Pinguet; F Portales; Sylvain Poujol; Emmanuelle Samalin; Simon Thezenas; A Thirion; Marc Ychou; Jean Pierre Bleuse; eric assenat
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Cancer chemotherapy and pharmacology 2012;69(3):807-14.
2012: Jaafar Bennouna; Christophe Borg; Olivier Bouché; Jean-Pierre Delord; Roger Faroux; Eric François; François Goldwasser; Faress Husseini; Sandrine Kraemer; Helene Senellart; Véronique Trillet-Lenoir; Marc Ychou; Jean-Yves Douillard
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Clinical colorectal cancer 2012;11(1):38-44.
2012: Alexandre Ho-Pun-Cheung; Christel Larbouret; eric assenat; Caroline Bascoul-Mollevi; Hervé Bazin; Florence Castan; Nadège Gaborit; Patrick Garnero; Gérard Mathis; André Pèlegrin; Jeanne Ramos; Marc Ychou; Evelyne Lopez-Crapez
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer.
PloS one 2012;7(7):e37065.
2012: Jean-Baptiste Bachet; Claude Bachmeyer; Rene J Bensadoun; Olivier Bouché; Brigitte Dreno; Pierre-Antoine Gourraud; Lucie Peuvrel; Ziad Reguiai; Marc Ychou; Thierry André
Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.
The oncologist 2012;17(4):555-68.
2011: Alexandre Ho-Pun-Cheung; eric assenat; Caroline Bascoul-Mollevi; Frédéric Bibeau; Florence Boissière-Michot; Dominic Cellier; David Azria; Philippe Rouanet; Pierre Senesse; Marc Ychou; Evelyne Lopez-Crapez
EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer.
International journal of cancer. Journal international du cancer 2011;128(12):2938-46.
2011: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; eric assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
The New England journal of medicine 2011;364(19):1817-25.
2011: Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1715-21.
2011: Romuald Le Scodan; Françoise Mornex; C Partensky; C Mercier; P-J Valette; Marc Ychou; F Bibeau; J-Y Scoazec
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2011;15(2):97-105.
2011: Jean-Bernard Dubois; Emmanuel Bussieres; Pierre Richaud; Philippe Rouanet; Yves Becouarn; Simone Mathoulin-Pélissier; Bernard Saint-Aubert; Marc Ychou
Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011;98(3):298-303.
2011: Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thierry Conroy; Antoine Adenis; Roger Faroux; Christine Rebischung; Loic Bergougnoux; Leila Kockler; Jean-Yves Douillard
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
International journal of cancer. Journal international du cancer 2011;128(3):682-90.
2011: eric assenat; Frédéric Bibeau; Jean Pierre Bleuse; Evelyne Crapez-Lopez; Françoise Desseigne; Andrew Kramar; Laurent Mineur; Fabienne Portales; Emmanuelle Samalin; Simon Thezenas; Frédéric Viret; Marc Ychou
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
The oncologist 2011;16(11):1557-64.
2011: Lucie Oberic; Didier Peiffert; Jean-Pierre Pignon; Frédéric Viret; Marc Ychou; Antoine Adenis; Charlotte Baey; Jaafar Bennouna; Jocelyne Berille; Patrice Celier; Françoise Mornex; Michel Ducreux
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Radiation oncology (London, England) 2011;6():124.
2011: Florent Mouliere; Bruno Robert; Marc Ychou; Erika Arnau Peyrotte; Maguy Del Rio; Celine Gongora; Franck Molina; alain roger thierry
High fragmentation characterizes tumour-derived circulating DNA.
PloS one 2011;6(9):e23418.
2010: Jacqueline Duffour; Simon Thézenas; Olivier Dereure; Agnès Garcin; Julie Caron; Emmanuelle Samalin; Fabienne Portales; Catherine Fiess; Patrick Chalbos; Christine Gestin-Boyer; Marc Ychou; Bernard Guillot
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
European journal of cancer (Oxford, England : 1990) 2010;46(18):3169-74.
2010: Laetitia Dahan; Franck bonnetain; Marc Ychou; Emmanuel Mitry; Mohamed Gasmi; Jean-Luc Raoul; Stéphane Cattan; Jean-Marc Phelip; Pascal Hammel; Bruno Chauffert; Pierre Michel; Jean-Louis Legoux; Philippe Rougier; Laurent Bedenne; Jean-François Seitz
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Gut 2010;59(11):1527-34.
2010: Olivier Turrini; Marc Ychou; Laurence Moureau-Zabotto; Philippe Rouanet; Marc Giovannini; Vincent Moutardier; D Azria; Jean-Robert Delpero; Frédéric Viret
Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2010;36(10):987-92.
2010: Franck bonnetain; Laetitia Dahan; Emilie Maillard; Marc Ychou; Emmanuel Mitry; Pascal Hammel; Jean-Louis Legoux; Philippe Rougier; Laurent Bedenne; Jean-François Seitz
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 2010;46(15):2753-62.
2010: alain roger thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.
Nucleic acids research 2010;38(18):6159-75.
2010: Nicolas Girard; Françoise Mornex; N Bossard; Marc Ychou; Bruno Chauffert; Virginie Wautot
Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
International journal of radiation oncology, biology, physics 2010;77(5):1426-32.
2009: Pierre Laurent-Puig; Anne Cayre; Gilles Manceau; Emmanuel Buc; Jean-Baptiste Bachet; Thierry Lecomte; Philippe Rougier; Astrid Lievre; Bruno Landi; Valérie Boige; Michel Ducreux; Marc Ychou; Fréderic Bibeau; Olivier Bouché; Julia Reid; Steven Stone; Frédérique Penault-Llorca
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):5924-30.
2009: eric assenat; Marc Ychou
[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
Bulletin du cancer 2009;96 Suppl():S41-6.
2009: Marc Ychou; W Hohenberger; S Thezenas; M Navarro; J Maurel; C Bokemeyer; E Shacham-Shmueli; F Rivera; C Kwok-Keung Choi; A Santoro
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(12):1964-70.
2009: Romuald Le Scodan; Françoise Mornex; N Girard; C Mercier; P-J Valette; Marc Ychou; F Bibeau; P Roy; Jean-Yves Scoazec; Christian Partensky
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1387-96.
2009: Mohamed Hebbar; Marc Ychou; Michel Ducreux
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.
Journal of cancer research and clinical oncology 2009;135(6):749-52.
2009: Alexandre Ho-Pun-Cheung; Caroline Bascoul-Mollevi; eric assenat; Frédéric Bibeau; Florence Boissière-Michot; Dominic Cellier; Marc Ychou; Evelyne Lopez-Crapez
Validation of an appropriate reference gene for normalization of reverse transcription-quantitative polymerase chain reaction data from rectal cancer biopsies.
Analytical biochemistry 2009;388(2):348-50.
2009: Frédéric Bibeau; Evelyne Lopez-Crapez; Frédéric Di Fiore; Simon Thezenas; Marc Ychou; France Blanchard; Aude Lamy; Frédérique Penault-Llorca; Thierry Frébourg; Pierre Michel; Jean-Christophe Sabourin; Florence Boissière-Michot
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(7):1122-9.
2009: Astrid Lièvre; Emmanuelle Samalin; Emmanuel Mitry; eric assenat; Christine Boyer-Gestin; Céline Lepère; Jean-Baptiste Bachet; Fabienne Portales; Jean-Nicolas Vaillant; Marc Ychou; Philippe Rougier
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
BMC cancer 2009;9():347.
2009: Alexandre Ho-Pun-Cheung; Caroline Bascoul-Mollevi; eric assenat; Florence Boissière-Michot; Frédéric Bibeau; Dominic Cellier; Marc Ychou; Evelyne Lopez-Crapez
Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization.
BMC molecular biology 2009;10():31.
2008: Romuald Le Scodan; Françoise Mornex; Christian Partensky; Catherine Mercier; Pierre-Jean Valette; Marc Ychou; Pascal Roy; Jean-Yves Scoazec
Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
American journal of clinical oncology 2008;31(6):545-52.
2008: Bruno Pereira; Sophie Gourgou-Bourgade; David Azria; Marc Ychou
Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5133-4; author reply 5134.
2008: Virginie Granci; Frédéric Bibeau; Andrew Kramar; Florence Boissière-Michot; Simon Thézénas; Agnès Thirion; Céline Gongora; Pierre Martineau; Maguy Del Rio; Marc Ychou
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
European journal of cancer (Oxford, England : 1990) 2008;44(15):2312-8.
2008: Marc Ychou; F Viret; Andrew Kramar; F Desseigne; E Mitry; Rosine Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Cancer chemotherapy and pharmacology 2008;62(2):195-201.
2008: Marc Ychou; David Azria; Cathy Menkarios; Patrick Faurous; François Quenet; Bernard Saint-Aubert; Philippe Rouanet; Monique Pèlegrin; Caroline Bascoul-Mollevi; Dominique Guerreau; Jean-Claude Saccavini; Jean-Pierre Mach; Jean-Claude Artus; André Pèlegrin
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3487-93.
2008: Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Frédéric Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):374-9.
2008: Frédéric Bibeau; Marie-Christine Chateau; Michel Guiu; eric assenat; David Azria; Rosy Lavaill; Marc Ychou; Florence Boissière-Michot
Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour.
Virchows Archiv : an international journal of pathology 2008;452(1):103-7.
2007: Sylvain Poujol; Frédéric Pinguet; Marc Ychou; Anissa Gauthey Abderrahim; Jacqueline Duffour; Françoise Bressolle
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Oncology reports 2007;18(6):1613-321.
2007: Yves Bécouarn; Pierre Senesse; S Thézenas; Eveline Boucher; Antoine Adenis; L Cany; Jacques-Henri Jacob; F Cvitkovic; C Montoto-Grillot; Marc Ychou
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(12):2000-5.
2007: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; FELICE GIULIANTE; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2037-45.
2007: Jacqueline Duffour; Sophie Gourgou; Françoise Desseigne; Charles Debrigode; Laurent Mineur; Frédéric Pinguet; Sylvain Poujol; Patrick Chalbos; Françoise Bressole; Marc Ychou
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2007;60(3):383-9.
2007: Alexandre Ho-Pun-Cheung; eric assenat; Simon Thezenas; Frédéric Bibeau; Philippe Rouanet; David Azria; Dominic Cellier; Jean Grenier; Marc Ychou; Pierre Senesse; Evelyne Lopez-Crapez
Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer.
International journal of radiation oncology, biology, physics 2007;68(4):1094-101.
2007: Emmanuelle Samalin; Marc Ychou
Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
Current opinion in oncology 2007;19(4):384-9.
2007: Jean-François Côté; Sylvain Kirzin; Andrew Kramar; Jean-François Mosnier; Marie-Danièle Diebold; Isabelle Soubeyran; Anne-Sophie Thirouard; Janick Selves; Pierre Laurent-Puig; Marc Ychou
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3269-75.
2007: Maguy Del Rio; Franck Molina; Caroline Bascoul-Mollevi; Virginie Copois; Frédéric Bibeau; Patrick Chalbos; Corinne Bareil; Andrew Kramar; Nicolas Salvetat; Caroline Fraslon; Emmanuel Conseiller; Virginie Granci; Benjamin Leblanc; Bernard Pau; Pierre Martineau; Marc Ychou
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):773-80.
2007: Virginie Copois; Frédéric Bibeau; Caroline Bascoul-Mollevi; Nicolas Salvetat; Patrick Chalbos; Corinne Bareil; Laurent Candeil; Caroline Fraslon; Emmanuel Conseiller; Virginie Granci; Pierre Mazière; Andrew Kramar; Marc Ychou; Bernard Pau; Pierre Martineau; Franck Molina; Maguy Del Rio
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality.
Journal of biotechnology 2007;127(4):549-59.
2006: Frédéric Bibeau; Marie-Christine Chateau; Cécile Borrelly; Marc Ychou; Philippe Rouanet
[An unusual liver metastasis].
Annales de pathologie 2006;26(6):455-6.
2006: Victoire Granger; eric assenat; Eric Barbotte; François Blanc; Pierre Blanc; Philippe Pouderoux; Marc Ychou; Pierre Senesse
Initial endoscopic description of esophageal squamous cell carcinomas.
Gastroentérologie clinique et biologique 2006;30(12):1365-70.
2006: Denis Pezet; Pierre Michel; Christine Rebischung; Marc Ychou
Cancer of the stomach.
Gastroentérologie clinique et biologique 2006;30 Spec No 2():2S16-2S23.
2006: Jacqueline Duffour; Olivier Bouché; Philippe Rougier; Chantal Milan; Laurent Bedenne; Jean-François Seitz; Bruno Buecher; Jean-Louis Legoux; Michel Ducreux; Denis Vetter; Jean-Luc Raoul; Eric François; Marc Ychou
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
Anticancer research 2006;26(5B):3877-83.
2006: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2212-21.
2006: Frédéric Bibeau; Florence Boissière-Michot; Jean-Christophe Sabourin; Sophie Gourgou-Bourgade; Michèle Radal; Frédérique Penault-Llorca; Philippe Rochaix; Laurent Arnould; Marie-Pierre Bralet; David Azria; Marc Ychou
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray.
Virchows Archiv : an international journal of pathology 2006;449(3):281-7.
2006: Sylvain Poujol; Françoise Bressolle; Jacqueline Duffour; Anissa Gauthey Abderrahim; Cécile Astre; Marc Ychou; Frédéric Pinguet
Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Cancer chemotherapy and pharmacology 2006;58(3):292-305.
2006: Françoise Mornex; Nicolas Girard; Jean-Yves Scoazec; Nadine Bossard; Marc Ychou; Denis Smith; Jean-François Seitz; Pierre-Jean Valette; Pascal Roy; Philippe Rouanet; Michel Ducreux; Christian Partensky
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
International journal of radiation oncology, biology, physics 2006;65(5):1471-8.
2006: eric assenat; Jacqueline Duffour; Marc Ychou
[Irinotecan for the treatment of metastatic colorectal cancer].
Bulletin du cancer 2006;93(5):507-15.
2006: Frédéric Bibeau; David Azria; Marie-Christine Chateau; Cécile Borrelly; Marc Ychou; François Quenet; Philippe Rouanet
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
Gastroentérologie clinique et biologique 2006;30(4):611-3.
2006: Marc Ychou; Olivier Bouché; F Marchal; Yacine Merrouche; Guillaume Gory-Delabaere
[Recommendations for clinical practice: management of stomach adenocarcinoma].
Bulletin du cancer 2006;93(2):192-6.
2006: Suzanne Nguyen; Christine Rebischung; Johan Van Ongeval; Michel Flesch; Mustapha Bennamoun; Thierry André; Marc Ychou; Erik Gamelin; Elisabeth Carola; Christophe Louvet
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.
Bulletin du cancer 2006;93(1):E1-6.
2005: Damien Pouessel; Simon Thezenas; Stéphane Culine; Catherine Becht; Pierre Senesse; Marc Ychou
Hepatic metastases from carcinomas of unknown primary site.
Gastroentérologie clinique et biologique 2005;29(12):1224-32.
2005: Eric François; Marc Ychou; Michel Ducreux; Frédérique Bertheault-Cvitkovic; Marc Giovannini; Thierry Conroy; Claire Lemanski; Olivier Thomas; Valérie Magnin
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.
European journal of cancer (Oxford, England : 1990) 2005;41(18):2861-7.
2005: David Azria; Nicolas Magné; Abderrahim Zouhair; Pierre Castadot; Stéphane Culine; Marc Ychou; Roger Stupp; Paul Van Houtte; Jean-Bernard Dubois; Mahmut Ozsahin
Radiation recall: a well recognized but neglected phenomenon.
Cancer treatment reviews 2005;31(7):555-70.
2005: Olivier Bouché; Marc Ychou; P Burtin; Laurent Bedenne; Michel Ducreux; G Lebreton; J Baulieux; B Nordlinger; C Martin; Jean-François Seitz; Jean-Marie Tigaud; E Echinard; Noël Stremsdoerfer; Chantal Milan; Philippe Rougier
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(9):1488-97.
2005: Michel Ducreux; Marc Ychou; Agnès Laplanche; Erick Gamelin; Philippe Lasser; Fares Husseini; François Quenet; Frédéric Viret; Jacques-Henri Jacob; Valérie Boige; Dominique Elias; Jean-Robert Delperro; Monique Luboinski
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4881-7.
2005: Evelyne Lopez-Crapez; Frédéric Bibeau; S Thézenas; Marc Ychou; Joelle Simony-Lafontaine; A Thirion; David Azria; Jean Grenier; Pierre Senesse
p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.
British journal of cancer 2005;92(12):2114-21.
2005: Marc Ychou; Guillaume Gory-Delabaere; Pierre Blanc; Lise Bosquet; Jacqueline Duffour; Marc Giovannini; François Guillemin; Claire Lemanski; Frédéric Marchal; Bruno Masson; Yacine Merrouche; Geneviève Monges; Antoine Adenis; Jean-François Bosset; Olivier Bouché; Thierry Conroy; Denis Pezet; Jean-Pierre Triboulet
[Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].
Bulletin du cancer 2005;92(4):381-409.
2005: Andrew Kramar; Sophie Gourgou-Bourgade; Marc Ychou
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):650; author reply 650-1.
2005: David Azria; Frédéric Bibeau; Nicolas Barbier; Abderrahim Zouhair; Claire Lemanski; Philippe Rouanet; Marc Ychou; Pierre Senesse; Mahmut Ozsahin; André Pèlegrin; Jean-Bernard Dubois; Simon Thèzenas
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.
BMC cancer 2005;5():62.
2005: Nicolas Plaisant; Pierre Senesse; David Azria; Claire Lemanski; Marc Ychou; François Quenet; Bernard Saint-Aubert; Philippe Rouanet
Surgery for esophageal cancer after concomitant radiochemotherapy: oncologic and functional results.
World journal of surgery 2005;29(1):32-8.
2004: David Azria; M Coelho; Christel Larbouret; Claire Lemanski; Antoine Serre; Marc Ychou; André Pèlegrin; Jean-Bernard Dubois; Stéphane Culine
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2004;8 Suppl 1():S106-13.
2004: Véronique Garambois; Fabienne Glaussel; Elodie Foulquier; Marc Ychou; Martine Pugnière; Robin X Luo; Binyam Bezabeh; André Pèlegrin
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.
BMC cancer 2004;4():75.
2004: Marc Ychou; Guillaume Gory-Delabaere; P Blanc; Lise Bosquet; Jacqueline Duffour; M Giovannini; F Guillemin; Claire Lemanski; F Marchal; Bruno Masson; Yacine Merrouche; G Monges; Antoine Adenis; J F Bosset; Olivier Bouché; T Conroy; Denis Pezet; Jean-Pierre Triboulet
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2004;8(5):322-35.
2004: Laurent Candeil; Isabelle Gourdier; Delphine Peyron; Nadia Vezzio; Virginie Copois; Frédéric Bibeau; Béatrice Orsetti; George L Scheffer; Marc Ychou; Qasim A Khan; Yves Pommier; Bernard Pau; Pierre Martineau; Maguy Del Rio
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
International journal of cancer. Journal international du cancer 2004;109(6):848-54.
2004: Damien Pouessel; Stéphane Culine; Catherine Becht; Marc Ychou; Gilles Romieu; Michel Fabbro; Didier Cupissol; Frédéric Pinguet
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Cancer 2004;100(6):1257-61.
2003: Jean-Bernard Dubois; David Azria; Marc Ychou
[External beam radiation therapy and interstitial brachytherapy in the treatment of anal canal carcinomas: a series of 70 patients].
Bulletin du cancer 2003;90(12):1107-10.
2003: David Azria; Christel Larbouret; Véronique Garambois; Andrew Kramar; Pierre Martineau; Bruno Robert; N Aillères; Marc Ychou; Jean-Bernard Dubois; André Pèlegrin
Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.
British journal of cancer 2003;89(10):1987-94.
2003: David Azria; Christel Larbouret; Bruno Robert; Stéphane Culine; Marc Ychou; Pierre Verrelle; Jean-Bernard Dubois; André Pèlegrin
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Bulletin du cancer 2003;90 Spec No():S202-12.
2003: Sylvain Poujol; Frédéric Pinguet; Françoise Malosse; Cécile Astre; Marc Ychou; Stéphane Culine; Françoise Bressolle
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Clinical chemistry 2003;49(11):1900-8.
2003: Frédéric Viret; Marc Ychou; Anthony Gonçalves; Vincent Moutardier; Valérie Magnin; Anne-Chantal Braud; J B Dubois; Erwan Bories; Gwenaelle Gravis; Jacques Camerlo; Dominique Genre; Dominique Maraninchi; Patrice Viens; Marc Giovannini
Docetaxel and radiotherapy and pancreatic cancer.
Pancreas 2003;27(3):214-9.
2003: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Charles Debrigode; Sophie Gourgou; Françoise Bressolle; Frédéric Pinguet
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Cancer chemotherapy and pharmacology 2003;52(4):282-90.
2003: David Fallik; Marc Ychou; J Jacob; P Colin; Jean-François Seitz; J Baulieux; Antoine Adenis; Jean-Yves Douillard; P Couzigou; R Mahjoubi; Michel Ducreux; Mondher Mahjoubi; Philippe Rougier
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):856-63.
2003: Damien Pouessel; Stéphane Culine; Catherine Becht; Gilles Romieu; Michel Fabbro; Marc Ychou; Didier Cupissol; Frédéric Pinguet
Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.
Anticancer research 2003;23(3C):2801-4.
2003: David Azria; Mylène Dorvillius; Sophie Gourgou; Pierre Martineau; Bruno Robert; Martine Pugnière; René Delard; Marc Ychou; Jean-Bernard Dubois; André Pèlegrin
Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody.
International journal of radiation oncology, biology, physics 2003;55(5):1363-73.
2003: Marc Ychou; Thierry Conroy; Jean-François Seitz; Sophie Gourgou; Aliette Hua; D Mery-Mignard; Andrew Kramar
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(3):481-9.
2002: Laurent Mineur; F Lacaine; Marc Ychou; Jean-François Bosset; Alain Daban
[Chemoradiotherapy in the adjuvant treatment of gastric adenocarcinomas: real progress?].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2002;6 Suppl 1():13s-23s.
2002: Jacqueline Duffour; Sophie Gourgou; Jean-François Seitz; Pierre Senesse; O Boutet; D Castera; Andrew Kramar; Marc Ychou
Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
Anticancer research 2002;22(6B):3727-31.
2002: Marc Ychou; Jean-Luc Raoul; Françoise Desseigne; C Borel; F X Caroli-Bosc; Jacques-Henri Jacob; Jean-François Seitz; Andrew Kramar; Aliette Hua; P Lefebvre; C Couteau; Yacine Merrouche
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2002;50(5):383-91.
2002: David Azria; Marc Ychou; William Jacot; Simon Thezenas; Claire Lemanski; Pierre Senesse; Patricia Prost; René Delard; Bruno Masson; Jean-Bernard Dubois
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
Pancreas 2002;25(4):360-5.
2002: Isabelle Gourdier; Maguy Del Rio; Laure Crabbé; Laurent Candeil; Virginie Copois; Marc Ychou; Charles Auffray; Pierre Martineau; Nadir Mechti; Yves Pommier; Bernard Pau
Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma.
FEBS letters 2002;529(2-3):232-6.
2002: Patricia Prost; Marc Ychou; David Azria
[Gemcitabine and pancreatic cancer].
Bulletin du cancer 2002;89 Spec No():S91-5.
2002: Michel Ducreux; Philippe Rougier; Jean-Pierre Pignon; Jean-Yves Douillard; Jean-François Seitz; Roland Bugat; J-F Bosset; Y Merouche; Jean-Luc Raoul; Marc Ychou; Antoine Adenis; F Berthault-Cvitkovic; Monique Luboinski
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1185-91.
2002: Jean-François Seitz; Jaafar Bennouna; Bernard Paillot; Erick Gamelin; Eric François; Thierry Conroy; Jean-Luc Raoul; Y Becouarn; Frédérique Bertheault-Cvitkovic; Marc Ychou; Salvador Nasca; A Fandi; P Barthelemy; Jean-Yves Douillard
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1072-9.
2002: David Azria; William Jacot; Patricia Prost; Stéphane Culine; Marc Ychou; Claire Lemanski; Jean-Bernard Dubois
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
Bulletin du cancer 2002;89(4):369-79.
2002: Stéphane Culine; Michel Fabbro; Marc Ychou; Gilles Romieu; Didier Cupissol; Frédéric Pinguet
Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
Cancer 2002;94(3):840-6.
2001: Marc Ychou; F Khemissa-Akouz; Andrew Kramar; Pierre Senesse; Jean Grenier
[A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
Bulletin du cancer 2001;88(10):1023-7.
2001: Stéphane Culine; Marc Ychou; Michel Fabbro; Gilles Romieu; Didier Cupissol
5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.
Anticancer research 2001;21(2B):1455-7.
2001: Pierre Senesse; F Khemissa; Claire Lemanski; Bruno Masson; François Quenet; Bernard Saint-Aubert; J Simony; Marc Ychou; Jean-Bernard Dubois; Philippe Rouanet
[Contribution of endorectal ultrasonography in preoperative evaluation for very low rectal cancer].
Gastroentérologie clinique et biologique 2001;25(1):24-8.
2000: Marc Ychou; Jean-Yves Douillard; Philippe Rougier; Antoine Adenis; Mireille Mousseau; P Dufour; J L Wendling; F Burki; Dominique Mignard; Michel Marty
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
American journal of clinical oncology 2000;23(2):143-8.
2000: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Sophie Gourgou; Jean Grenier
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Disease markers 2000;16(3-4):105-10.
1999: Michel Ducreux; Marc Ychou; Jean-François Seitz; Marc Bonnay; A Bexon; Jean-Pierre Armand; Mondher Mahjoubi; Dominique Méry-Mignard; Philippe Rougier
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2901-8.
1999: A Leconte; Véronique Garambois; Marc Ychou; Bruno Robert; Didier Pourquier; Alexey V Terskikh; Jean-Pierre Mach; André Pèlegrin
Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model.
British journal of cancer 1999;80(9):1373-9.
1999: Marc Ychou; Jacqueline Duffour; Frédéric Pinguet; Andrew Kramar; JM Joulia; D Topart; Françoise Bressolle
Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.
Anticancer research 1999;19(3B):2229-35.
1999: Jean-Claude Barbare; Laurent Bedenne; Olivier Bouché; Guillaume Cadiot; Gilles Calais; Loïk de Calan; Thierry Conroy; Michel Ducreux; Pierre-Luc Etienne; D Elias; J Faivre; Jean-Louis Legoux; Philippe Maingon; F Mornex; Bernard Nordlinger; Jean-Claude Ollier; Didier Peiffert; G Pelletier; P Rat; Philippe Rougier; A Ruskone-Fourmestraux; Jean-François Seitz; J P Triboulet; Jean-Claude Trinchet; Marc Ychou
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)].
Gastroentérologie clinique et biologique 1999;23(5):486-96.
1999: Stéphane Culine; Michel Fabbro; Marc Ychou; Gilles Romieu; Didier Cupissol; H Pujol
Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):569-75.
1999: Jean-Claude Barbare; Laurent Bedenne; Olivier Bouché; Guillaume Cadiot; Gilles Calais; Loïk de Calan; Thierry Conroy; Michel Ducreux; Pierre-Luc Etienne; D Elias; J Faivre; Jean-Louis Legoux; Philippe Maingon; F Mornex; Bernard Nordlinger; Jean-Claude Ollier; Didier Peiffert; G Pelletier; P Rat; Philippe Rougier; A Ruskone-Fourmestraux; Jean-François Seitz; J P Triboulet; Jean-Claude Trinchet; Marc Ychou
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)].
Gastroentérologie clinique et biologique 1999;23(4):502-12.
1999: JM Joulia; Frédéric Pinguet; Marc Ychou; Jacqueline Duffour; Cécile Astre; Françoise Bressolle
Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
European journal of cancer (Oxford, England : 1990) 1999;35(2):296-301.
1999: Françoise Bressolle; JM Joulia; Frédéric Pinguet; Marc Ychou; Cécile Astre; Jacqueline Duffour; Roberto Gomeni
Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 1999;44(4):295-302.
1998: Michel Ducreux; Marian Gil-Delgado; T André; Marc Ychou; A de Gramond; David Khayat
[Irinotecan in combination for colon cancer].
Bulletin du cancer 1998;Spec No():43-6.
1998: Stéphane Culine; L Gazagne; Marc Ychou; Gilles Romieu; Michel Fabbro; Didier Cupissol; Jean-Bernard Dubois
[Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1998;19(10):713-9.
1998: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Jean Grenier
Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
Oncology reports 1998;5(5):1245-50.
1998: Yves Bécouarn; Marc Ychou; Michel Ducreux; C Borel; Frédérique Bertheault-Cvitkovic; Jean-François Seitz; Salvador Nasca; T D Nguyen; Bernard Paillot; Jean-Luc Raoul; Jacqueline Duffour; A Fandi; G Dupont-André; Philippe Rougier
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2739-44.
1998: Marc Ychou; Andre Pelegrin; P Faurous; Bruno Robert; J C Saccavini; D Guerreau; Jean-François Rossi; Michel Fabbro; Franz Buchegger; Jean-Pierre Mach; J C Artus
Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
International journal of cancer. Journal international du cancer 1998;75(4):615-9.
1998: Marc Ychou; Pierre Senesse; François Quenet
[Update on gastroenterology].
Bulletin du cancer 1998;85(1):37-41.
1997: Stéphane Culine; Michel Fabbro; C Assens; Marc Ychou; Gilles Romieu; Andrew Kramar; Didier Cupissol; Frédéric Pinguet; H Pujol
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):951-6.
1997: JM Joulia; Frédéric Pinguet; Marc Ychou; Jacqueline Duffour; D Topart; PY Grosse; Cécile Astre; Françoise Bressolle
Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).
Anticancer research 1997;17(4A):2727-30.
1997: Philippe Rougier; Roland Bugat; Jean-Yves Douillard; Stéphane Culine; E Suc; P Brunet; Y Becouarn; Marc Ychou; Michel Marty; Jean-Marc Extra; Jacques Bonneterre; Antoine Adenis; Jean-François Seitz; Gérard Ganem; Moïse Namer; Thierry Conroy; Sylvie Negrier; Yacine Merrouche; F Burki; Mireille Mousseau; P Herait; Mondher Mahjoubi
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):251-60.
1996: Bruno Robert; Jean-Pierre Mach; J C Mani; Marc Ychou; S Folli; J C Artus; André Pèlegrin
Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Cancer research 1996;56(20):4758-65.
1996: Marc Ychou; Cécile Astre; Philippe Rouanet; J M Fabre; B Saint-Aubert; J Domergue; D Ribard; A J Ciurana; C Janbon; H Pujol
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):1933-7.
1996: D Machover; Eduardo Diaz-Rubio; A de Gramont; A Schilf; J J Gastiaburu; Silvano Brienza; M Itzhaki; G Metzger; D N'Daw; J Vignoud; Albert Abad; E Francois; Erick Gamelin; Michel Marty; Javier Sastre; Jean-François Seitz; Marc Ychou
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):95-8.
1995: Marc Ychou; M Veyrac; B Hanslik; M Abouhafss; J P Daures; Pascal Perney; J Pinto; Jean-Michel Bruel; François Blanc; H Michel
[Prognostic factors of hepatocellular carcinoma: a multivariate analysis in 113 patients].
Bulletin du cancer 1995;82(11):971-4.
1995: Philippe Rouanet; J M Fabre; J B Dubois; F Dravet; B Saint Aubert; J Pradel; Marc Ychou; C Solassol; H Pujol
Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results.
Annals of surgery 1995;221(1):67-73.
1994: G Boilleau; Jean-Louis Pujol; Marc Ychou; P Faurous; Charles-Henri Marty-Ané; François-Bernard Michel; Philippe Godard
Detection of lymph node metastases in lung cancer: comparison of 131I-anti-CEA-anti-CA 19-9 immunoscintigraphy versus computed tomography.
Lung cancer (Amsterdam, Netherlands) 1994;11(3-4):209-19.
1994: Philippe Rougier; Mondher Mahjoubi; Philippe Lasser; Michel Ducreux; J Oliveira; Marc Ychou; Jean-Pierre Pignon; Dominique Elias; S Bellefqih; C Bognel
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1269-75.
1994: Philippe Rougier; Michel Ducreux; Mondher Mahjoubi; Jean-Pierre Pignon; S Bellefqih; J Oliveira; C Bognel; Philippe Lasser; Marc Ychou; Dominique Elias
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1263-9.
1994: Philippe Rouanet; F Dravet; J B Dubois; B Saint Aubert; M Veyrac; Marc Ychou; C Solassol; H Pujol
[Proctectomy and colo-anal anastomosis after high-dose irradiation of cancers of the lower third of the rectum. Functional and oncological results].
Annales de chirurgie 1994;48(6):512-9.
1993: Marc Ychou; Marcel Ricard; Jean Lumbroso; P Rougier; Jean-Pierre Mach; F Buchegger; J C Saccavini; Philippe Lasser; D Elias; F Eschwege
Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1105-11.
1992: Marc Ychou; T Tuszinski; Jean-Pierre Pignon; Jean-Michel Bidart; Dominique Bellet; C Bohuon; Philippe Rougier
[Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].
Gastroentérologie clinique et biologique 1992;16(11):848-52.
1991: J Gutknecht; D Larrey; Marc Ychou; Y Fedkovic; C Janbon
[Severe ischemic hepatitis after taking cibenzoline].
Annales de gastroentérologie et d'hépatologie 1991;27(6):269-70.
1990: Jean-Pierre Mach; F Buchegger; A Pelegrin; Marc Ychou; Marcel Ricard; J Lumbroso; P Rougier; P Lasser; D Elias; J C Saccavini
Radioimmunotherapy of colon carcinoma with I-131 labeled antibodies, successful experimental results and clinical dosimetry study.
Pathologie-biologie 1990;38(8):819.
1989: Philippe Rougier; Marc Ychou; Jean-Michel Bidart; Dominique Bellet
[Usefulness of tumor markers in hepatogastroenterology].
Gastroentérologie clinique et biologique 1989;13(2 Pt 3):T1-5.
1988: Philippe Rougier; Marc Ychou; Jean Pierre Droz
[Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)].
Bulletin du cancer 1988;75(10):979-81.